OncoCyte’s pipeline diagnostics are being developed as Multianalyte Assays with Algorithmic Analyses (MAAAs), which look at the differential expression of biomarkers (analytes) in specific types of cancer and use proprietary algorithms to score a patient’s probability of having cancer. The assays are being developed as rule out tests with a very high sensitivity.  We are focused on cancers with the highest unmet clinical need, which OncoCyte believes will present significant commercial opportunities that both improve patient outcomes and reduce healthcare spend.

The Company’s primary focus is on our lung confirmatory assay.  The assay will help identity which patients with a suspicious pulmonary nodule may not benefit from a follow-up biopsy.   This would result in reducing unnecessary lung biopsies that are risky to the patient and costly for the healthcare system.